Steven Mah
Stock Analyst at TD Cowen
(1.98)
# 2,702
Out of 4,754 analysts
32
Total ratings
33.33%
Success rate
6.91%
Average return
Main Sectors:
Stocks Rated by Steven Mah
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TWST Twist Bioscience | Reiterates: Buy | $58 | $37.11 | +56.29% | 3 | Nov 26, 2024 | |
| BLFS BioLife Solutions | Maintains: Buy | $28 → $31 | $24.51 | +26.48% | 2 | Nov 13, 2024 | |
| DNA Ginkgo Bioworks Holdings | Maintains: Outperform | $280 → $120 | $8.01 | +1,398.13% | 2 | Mar 1, 2024 | |
| RXRX Recursion Pharmaceuticals | Initiates: Market Perform | n/a | $6.59 | - | 1 | Jan 26, 2024 | |
| SDGR Schrödinger | Initiates: Outperform | $42 | $21.24 | +97.74% | 1 | Jan 26, 2024 | |
| ABCL AbCellera Biologics | Initiates: Outperform | n/a | $2.36 | - | 1 | Feb 28, 2023 | |
| OABI OmniAb | Initiates: Outperform | $10 | $3.42 | +192.40% | 1 | Feb 22, 2023 | |
| ME 23andMe Holding Co. | Initiates: Outperform | $120 | $1.47 | +8,063.27% | 1 | Sep 22, 2022 | |
| ABSI Absci | Upgrades: Outperform | n/a | $3.42 | - | 1 | Aug 12, 2022 | |
| CDXS Codexis | Maintains: Outperform | $39 → $21 | $2.74 | +667.82% | 2 | Jul 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $150 → $155 | $143.11 | +8.31% | 4 | Jul 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $28 | $1.55 | +1,706.45% | 1 | May 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $135 → $140 | $15.28 | +816.23% | 3 | Mar 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $20 → $52 | $1.32 | +3,854.37% | 3 | Feb 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $340 → $415 | $84.20 | +392.87% | 4 | Dec 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $40 → $80 | $2.78 | +2,777.70% | 1 | Dec 16, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $168 → $250 | $39.05 | +540.20% | 1 | Jul 8, 2020 |
Twist Bioscience
Nov 26, 2024
Reiterates: Buy
Price Target: $58
Current: $37.11
Upside: +56.29%
BioLife Solutions
Nov 13, 2024
Maintains: Buy
Price Target: $28 → $31
Current: $24.51
Upside: +26.48%
Ginkgo Bioworks Holdings
Mar 1, 2024
Maintains: Outperform
Price Target: $280 → $120
Current: $8.01
Upside: +1,398.13%
Recursion Pharmaceuticals
Jan 26, 2024
Initiates: Market Perform
Price Target: n/a
Current: $6.59
Upside: -
Schrödinger
Jan 26, 2024
Initiates: Outperform
Price Target: $42
Current: $21.24
Upside: +97.74%
AbCellera Biologics
Feb 28, 2023
Initiates: Outperform
Price Target: n/a
Current: $2.36
Upside: -
OmniAb
Feb 22, 2023
Initiates: Outperform
Price Target: $10
Current: $3.42
Upside: +192.40%
23andMe Holding Co.
Sep 22, 2022
Initiates: Outperform
Price Target: $120
Current: $1.47
Upside: +8,063.27%
Absci
Aug 12, 2022
Upgrades: Outperform
Price Target: n/a
Current: $3.42
Upside: -
Codexis
Jul 15, 2022
Maintains: Outperform
Price Target: $39 → $21
Current: $2.74
Upside: +667.82%
Jul 6, 2021
Maintains: Overweight
Price Target: $150 → $155
Current: $143.11
Upside: +8.31%
May 11, 2021
Initiates: Overweight
Price Target: $28
Current: $1.55
Upside: +1,706.45%
Mar 5, 2021
Maintains: Overweight
Price Target: $135 → $140
Current: $15.28
Upside: +816.23%
Feb 11, 2021
Upgrades: Overweight
Price Target: $20 → $52
Current: $1.32
Upside: +3,854.37%
Dec 22, 2020
Upgrades: Overweight
Price Target: $340 → $415
Current: $84.20
Upside: +392.87%
Dec 16, 2020
Upgrades: Overweight
Price Target: $40 → $80
Current: $2.78
Upside: +2,777.70%
Jul 8, 2020
Maintains: Overweight
Price Target: $168 → $250
Current: $39.05
Upside: +540.20%